Patents Assigned to Entelos, Inc.
-
Patent number: 11860960Abstract: A computer-implemented method may include: providing an extension for a web browser, the extension having a user interface configured to occupy a portion of a user interface associated with the web browser; intercepting content fetched by the web browser for a web page being a company page, a social media page, or a professional page; processing the fetched content for the web page to extract information including: a company name, a candidate name, a job title, and/or an industry name; querying a database for contextual information based on the extracted information, the contextual information being a summary of information obtained from one or more sources other than the web page; and presenting, via the user interface, the contextual information including: company information based on the company name, candidate information based on the candidate name, job title information based on the job title, and/or industry information based on the industry name.Type: GrantFiled: April 15, 2019Date of Patent: January 2, 2024Assignee: Entelo, Inc.Inventors: Chin Keong Ling, Ryan Booth, Max Schultz, Haroon Rasheed Paul Mohamed, Yangxu Mao, Gaurav Kataria
-
Patent number: 11853397Abstract: In some embodiments, status scores representing the status of an entity at various times are determined. Classifiers may be used to translate the status scores into status levels, and visual representations of the progression of the entity's status levels over time may be generated. In some embodiments, predictive models are used to detect outlying events and entities based on the status scores. Some predictive models may be used to predict whether an entity is an outlying candidate for a transition from one state to another state. Other predictive models may be used to predict whether an entity is an outlier relative to a group of other entities.Type: GrantFiled: October 2, 2018Date of Patent: December 26, 2023Assignee: Entelo, Inc.Inventors: Chin Keong Ling, Cole Walter Goeppinger, Haroon Rasheed Paul Mohamed
-
Patent number: 9734207Abstract: Entity resolution techniques and systems are described. An entity resolution method may include estimating a joint probability of occurrence of a plurality of values of a respective plurality of descriptors of an entity. The plurality of descriptor values may be included in a first data set. The method may further include determining that the joint probability of occurrence of the plurality of descriptor values is less than a threshold probability, identifying a second data set including the same plurality of values of the same respective plurality of descriptors, and determining, based at least in part on the joint probability of occurrence of the plurality of descriptor values being less than the threshold probability and on the first and second data sets including the same plurality of descriptor values, that the first and second data sets describe the same entity.Type: GrantFiled: December 28, 2015Date of Patent: August 15, 2017Assignee: Entelo, Inc.Inventors: Cole W. Goeppinger, James C. Hwang, Ayumi A. Yu, John H. McGrath, Jr., Thomas B. Benner, Gilles Pirio
-
Publication number: 20110275527Abstract: Methods and apparatus to identify a potential toxicity of a therapy in a biological system are described. In one embodiment, a method uses a computer model that represents a set of biological processes of the biological system. The method includes executing the computer model to identify a first set of biological processes contributing to the occurrence of a toxic state of the biological system. The method also includes identifying a set of biological assays based on the first set of biological processes and testing the therapy in the set of biological assays to identify a second set of biological processes modified by the therapy. The method further includes identifying the potential toxicity of the therapy based on the second set of biological processes.Type: ApplicationFiled: December 14, 2010Publication date: November 10, 2011Applicant: ENTELOS, INC.Inventors: Seth Gary Michelson, Alex Lawrence Bangs
-
Publication number: 20100324874Abstract: The invention encompasses systems, methods, and apparatus for predicting and monitoring an individual's response to a therapeutic regimen. The invention includes multiple virtual patients, an associating subsystem operable to associate the subject with one or more of the virtual patients, and a simulation engine operable to apply one or more experimental protocols to the one or more virtual patients identified with the subject to generate a set of outputs.Type: ApplicationFiled: October 7, 2004Publication date: December 23, 2010Applicant: Entelos, Inc.Inventors: Alex Bangs, Kevin Bowling, Thomas Paterson
-
Patent number: 7853406Abstract: Methods and apparatus to identify a potential toxicity of a therapy in a biological system are described. In one embodiment, a method uses a computer model that represents a set of biological processes of the biological system. The method includes executing the computer model to identify a first set of biological processes contributing to the occurrence of a toxic state of the biological system. The method also includes identifying a set of biological assays based on the first set of biological processes and testing the therapy in the set of biological assays to identify a second set of biological processes modified by the therapy. The method further includes identifying the potential toxicity of the therapy based on the second set of biological processes.Type: GrantFiled: June 13, 2003Date of Patent: December 14, 2010Assignee: Entelos, Inc.Inventors: Seth Gary Michelson, Alex Lawrence Bangs
-
Patent number: 7778782Abstract: The present invention includes methods and apparatus for use in rapid testing for and prediction of a PPAR? response (i.e. a response similar to that of PPAR? agonists). The invention includes a PPAR? response signature comprising a set of twenty genes. The invention discloses methods whereby the differential expression of the genes of the PPAR? response signature may be used to predict whether a compound will induce a PPAR? response in a test subject.Type: GrantFiled: December 16, 2003Date of Patent: August 17, 2010Assignee: Entelos, Inc.Inventors: Cecelia Pearson, Michael Furness, Stuart Tugendreich, Georges Natsoulis
-
Patent number: 7774182Abstract: An apparatus and method for validating a computer model is described. In one embodiment, a computer-readable medium comprises instructions to associate a set of configurations of a computer model with a stimulus-response test, each configuration of the set of configurations representing a different model scenario, the stimulus-response test defining a modification to each configuration of the set of configurations. The computer-readable medium also comprises instructions to apply the stimulus-response test to the set of configurations to produce a simulated response for each configuration of the set of configurations and instructions to compare the simulated responses for the set of configurations with an expected response to the stimulus-response test.Type: GrantFiled: September 10, 2008Date of Patent: August 10, 2010Assignee: Entelos, Inc.Inventor: Thomas Paterson
-
Publication number: 20100120050Abstract: The invention also provides methods, apparatuses and reagents useful for predicting future atherosclerosis based on expression levels of genes selected from the set of 68 genes with differential expression in response to pioglitazone and rosiglitazone. The invention also discloses reagent sets and biomarkers for predicting progression of atherosclerosis induced by anti-diabetic therapy in a subject. In one particular embodiment the invention provides a method for predict whether a compound will induce atherosclerosis using gene expression data from sub-acute treatments.Type: ApplicationFiled: November 11, 2009Publication date: May 13, 2010Applicant: ENTELOS, INC.Inventors: Kapil Gadkar, Ananth Kadambi, Cecelia Pearson, Lynn Powell, Scott Siler, Jeff Trimmer
-
Patent number: 7654955Abstract: Apparatus and methods for assessing metabolic substrate utilization are described. In one embodiment, a processor-readable medium includes code to receive data indicative of a plasma glucose concentration, a plasma free fatty acid concentration, and a respiratory quotient of a subject. The processor-readable medium also includes code to calculate, based on the data, respective values of a set of metabolic parameters. The set of metabolic parameters includes a first metabolic parameter and a second metabolic parameter. The value of the first metabolic parameter is indicative of whether the subject has a predisposition towards oxidation of a first type of metabolic substrate or a second type of metabolic substrate, and the value of the second metabolic parameter is indicative of the subject's responsiveness to a change in availability of the first type of metabolic substrate or the second type of metabolic substrate.Type: GrantFiled: November 19, 2004Date of Patent: February 2, 2010Assignee: Entelos, Inc.Inventors: David Polidori, Kevin Hall
-
Patent number: 7588892Abstract: The invention discloses reagent sets and gene signatures for predicting onset of renal tubule injury in a subject. The invention also provides a necessary set of 186 genes useful for generating signatures of varying size and performance capable of predicting onset of renal tubule injury. The invention also provides methods, apparatuses and reagents useful for predicting future renal tubule injury based on expression levels of genes in the signatures. In one particular embodiment the invention provides a method for predict whether a compound will induce renal tubule injury using gene expression data from sub-acute treatments.Type: GrantFiled: July 18, 2005Date of Patent: September 15, 2009Assignee: Entelos, Inc.Inventors: Georges Natsoulis, Mark Fielden, Kurt Jarnagin, Kyle Kolaja
-
Publication number: 20090150134Abstract: The invention encompasses systems, methods, and apparatus for predicting clinical outcomes and monitoring an individual's response to a therapeutic regimen. The invention further encompasses methods for predicting cardiovascular risk based a genetic marker status and methods for modifying a computer to reflect genetic data and for incorporating genetic markers into a virtual population.Type: ApplicationFiled: November 12, 2008Publication date: June 11, 2009Applicant: ENTELOS, INC.Inventors: Hector De Leon, Kapil Gadkar, Ananth Kadambi, Thomas S. Paterson, Lyn Powell
-
Publication number: 20090132219Abstract: An apparatus and method for validating a computer model is described. In one embodiment, a computer-readable medium comprises instructions to associate a set of configurations of a computer model with a stimulus-response test, each configuration of the set of configurations representing a different model scenario, the stimulus-response test defining a modification to each configuration of the set of configurations. The computer-readable medium also comprises instructions to apply the stimulus-response test to the set of configurations to produce a simulated response for each configuration of the set of configurations and instructions to compare the simulated responses for the set of configurations with an expected response to the stimulus-response test.Type: ApplicationFiled: September 10, 2008Publication date: May 21, 2009Applicant: Entelos, Inc.Inventor: Thomas S. PATERSON
-
Patent number: 7519519Abstract: Disclosed is a method for predicting the biological activity of a compound by the similarity of its drug signature score to the scores of a plurality of known drug signatures.Type: GrantFiled: December 18, 2003Date of Patent: April 14, 2009Assignee: Entelos, Inc.Inventors: Barrett P. Eynon, Georges Natsoulis, Kurt Jarnigan
-
Patent number: 7472050Abstract: The present invention relates to a mathematical and computer model of a joint. The model includes representation of the biological processes related to the synovial tissue and cartilage. In one embodiment, the model represents a human joint afflicted with rheumatoid arthritis.Type: GrantFiled: February 11, 2005Date of Patent: December 30, 2008Assignee: Entelos, Inc.Inventors: Nadine A. Defranoux, Todd B. Dubnicoff, David J. Klinke, II, Annette K. Lewis, Thomas S. Paterson, Saroja Ramanujan, Lisl K. M. Shoda, Karl Petter Soderstrom, Herbert K. Struemper
-
Patent number: 7467118Abstract: The invention relates to improved methods and computer-based systems and software products useful for deriving and optimizing linear classifiers based on an adjusted sparse linear programming methodology (A-SPLP). This methodology is based on minimizing an objective function, wherein the objective function includes a loss term representing the performance of the objective function on a training dataset comprising at least two separate, adjustable weighting constants associated with classification errors for data points in-class and not-in-class, respectively.Type: GrantFiled: January 12, 2006Date of Patent: December 16, 2008Assignee: Entelos Inc.Inventor: Gert R. G. Lanckriet
-
Patent number: 7422854Abstract: The present invention provides methods and compositions for use in rapid test or prediction of the propensity of a test compound to induce cholesterol reduction in a subject. The invention also includes a cholesterol reduction signature as well as the method of deriving such signature.Type: GrantFiled: December 18, 2003Date of Patent: September 9, 2008Assignee: Entelos, Inc.Inventors: Georges Natsoulis, Stuart Tugendreich, Cecelia Pearson, Michael Furness
-
Publication number: 20080213786Abstract: The invention encompasses a novel method of treating an inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases, such as rheumatoid arthritis, and their clinical symptoms. The inventors have made the discovery that the activity of galectin-3, a ?-galactoside-binding lectin known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of an inflammatory disease, such as rheumatoid arthritis, may be alleviated by administering a compound that inhibits the activity of galectin-3.Type: ApplicationFiled: April 11, 2008Publication date: September 4, 2008Applicant: Entelos, Inc.Inventors: Vincent Jacques Hurez, Seth G. Michelson, Herbert Struemper, Leif Gustaf Wennerberg
-
Patent number: 7396645Abstract: The present invention provides methods and compositions for use in rapid test or prediction of the propensity of a test compound to induce cholestasis in a subject. The invention also includes a Cholestasis signature database as well as the method of deriving such database.Type: GrantFiled: December 16, 2003Date of Patent: July 8, 2008Assignee: Entelos, Inc.Inventors: Georges Natsoulis, Cecelia Pearson, Stuart Tugendreich, Michael Furness
-
Patent number: 7353152Abstract: The present invention relates generally to a mathematical and computer model of diabetes related disorders (e.g., human type 2 diabetes) within the framework of multiple macronutrient metabolism. The model includes a representation of complex physiological control mechanisms directing, for example, fat metabolism, protein metabolism and/or carbohydrate metabolism. In one embodiment, for example, the model can account for the interconversion between macronutrients, as well as their digestion, absorption, storage, mobilization, and adaptive utilization, as well as the endocrine control of these processes. In this embodiment, the model can simulate, for example, a heterogeneous group of diabetes related disorders, from insulin resistant to severe diabetic, and can predict the likely effects of therapeutic interventions.Type: GrantFiled: January 9, 2002Date of Patent: April 1, 2008Assignee: Entelos, Inc.Inventors: Paul Brazhnik, Kevin Hall, Dave Polidori, Scott Siler, Jeff Trimmer